Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Lucretius who wrote (104508)	5/24/2001 11:48:10 AM
From: patron_anejo_por_favor	Read Replies (1) \| Respond to of 436258

This could be the very dumbest thing I've ever seen in an analysts report (on Genome Therapeutics): marketwatch.com In a unique twist on a valuation model, Ladenburg said it values genomics companies by the level of their research and development spending - the more they spend, the more they're worth. When using this metric, Genome is "substantially undervalued," according to Ladenburg. Absolutely, f*cking brilliant! The more cash we burn (doesn't matter WHO is doing the research, and if they're cost-efficient, so much the worse), the better! It's not our money anyway, it is (was) yours! Disclosure: Short GENE as of today.